Publication Topic

Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I, et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045.

Minshall ME, Liu Y, Wagner A, Jensen IS, Corman S. The cost for of chronic lung allograft dysfunction (CLAD) in lung transplant (LTX) recipients by stage 1-4: A claims database analysis. Abstract EE70. ISPOR 2024.

Garrison K, Zhang W, Jensen I, Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303. ISPOR EU 2023.

Jensen I, Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539. ISPOR 2023.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

Jensen I, Cyr P. 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive.

Yao W, Jensen I, Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi:  10.5863/1551-6776-27.8.695.

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24. ISPOR 2022.

Pang F, Dean R, Jensen I, Olaye A, Miller B. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Abstract PRO30. ISPOR 2021.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin lymphoma in the United States: A budgetary impact analysis. Abstract C14. Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo 2014.